Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

被引：57

作者：

Jankovic, J.

Hunter, C.

Dolimbek, B. Z.

Dolimbek, G. S.

Adler, C. H.

Brashear, A.

Comella, C. L.

Gordon, M.

Riley, D. E.

Sethi, K.

Singer, C.

Stacy, M.

Tarsy, D.

Atassi, M. Z.

机构：

[1] Baylor Coll Med, Parkinsons Dis Ctr, Dept Neurol, Houston, TX 77030 USA

[2] Mayo Clin Scottsdale, Scottsdale, AZ USA

[3] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA

[4] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[5] Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA

[6] Univ Hosp Cleveland, Cleveland, OH 44106 USA

[7] Med Coll Georgia, Augusta, GA 30912 USA

[8] Univ Miami, Miami, FL 33152 USA

[9] Barrow Neurol Inst, Phoenix, AZ 85013 USA

[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

NEUROLOGY | 2006年 / 67卷 / 12期

关键词：

D O I：

10.1212/01.wnl.0000249308.66959.43

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long- term efficacy.

引用

页码：2233 / 2235

页数：3

共 10 条

[1]

The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences [J].